Bio-Rad Laboratories Inc has 8 Schedule 13D or 13G filings on record since 2025-07-18. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Norman D. Schwartz | 97.2% | 4,929,036 | SCHEDULE 13D/A, 2025-10-30 | 2025-09-25 |
| Alice N. Schwartz | 12.3% | 2,732,073 | SCHEDULE 13D/A, 2025-07-18 | 2025-05-01 |
| First Eagle Investment Management, LLC | 11.4% | 2,528,321 | SCHEDULE 13G/A, 2025-08-06 | 2025-06-30 |
| BlackRock, Inc. | 7.4% | 1,618,123 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Purpose of Transaction (Item 4)
Alice N. Schwartz
Item 4 to the Schedule 13D is hereby amended, in pertinent part, as follows: The purposes of the transactions on December 10, 2018, December 3, 2019, December 7, 2020, November 9, 2021, November 7, 2022, December 5, 2023 and August 26, 2024 for Alice N. Schwartz and for the Alice N. Schwartz Revocable Trust set forth in Item 5 were estate planning. The purpose of the Shareholders' ownership of Bio-Rad shares has been control of the Company. Mrs. Schwartz, along with other members of her family, control the management of the Company and may be deemed to be a "parent" of the Company as that term is defined in the Rules and Regulations of the Commission.Item 4 of the SCHEDULE 13D/A filed 2025-07-18
Norman D. Schwartz
Item 4 to the Schedule 13D is hereby amended, in pertinent part, as follows: The purpose of the Shareholders' ownership of Bio-Rad shares has been control of the Company. The Shareholders control the management of the Company and may be deemed to be "parents" of the Company as that term is defined in the Rules and Regulations of the Commission.Item 4 of the SCHEDULE 13D/A filed 2025-10-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-18 | Alice N. Schwartz | 12.3% | SCHEDULE 13D/A |
| 2025-08-06 | First Eagle Investment Management, LLC | 11.4% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 7.4% | SCHEDULE 13G/A |
| 2025-10-28 | Norman D. Schwartz | 14.6% | SCHEDULE 13D/A |
| 2025-10-28 | Norman D. Schwartz | 97.2% | SCHEDULE 13D/A |
| 2025-10-30 | Norman D. Schwartz | 14.6% | SCHEDULE 13D/A |
| 2025-10-30 | Norman D. Schwartz | 97.2% | SCHEDULE 13D/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Bio-Rad Laboratories Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.